Pfizer Investor Presentation — April 2020

Document content

First Quarter 2020 Earnings

Senior Vice President, Investor Relations 3 Forward -Looking Statements and Non- GAAP Financial Information

 Our discussions during this conference call will include forward -looking statements about, among other things, our anticipated future operating and

financial performance, business plans and prospects, expectations for our product pipeline, in -line products and product candidates, including

anticipated regulatory submissions, data read -outs, study starts, approvals, revenue contribution, growth, performance, timing o f exclusivity and

potential benefits, strategic reviews, capital allocation objectives, the benefits anticipated from the reorganization of our commercial operations in

2019, plans for and prospects of our acquisitions and other business development activities, including our proposed transacti on with Mylan N.V.

(Mylan) to combine Upjohn and Mylan to create a new global pharmaceutical company, our acquisition of Array BioPharma Inc. and o ur

transaction with GlaxoSmithKline plc which combined our respective consumer healthcare businesses into a new consumer healthc are joint

venture, our ability to successfully capitalize on growth opportunities and prospects, manufacturing and product supply, our eff orts to respond to

COVID-19, our expectations regarding the impact of COVID-19 on our business, operations and financial results and plans relating to share

repurchases and dividends that are subject to substantial risks and uncertainties that could cause actual results to differ m aterially from those

expressed or implied by such statements. These statements are subject to risks, uncertainties and other factors that may caus e actual results to

differ materially from past results, future plans and projected future results. Additional information regarding these and ot her factors can be found